Five patients from across the U.S. say early diagnosis and anti-amyloid treatments gave them more time and independence. Brent Beasley, Lori Baetz, Ralph Carmona, Kathi Rigby and Michael B. describe regained routines, resumed roles and concrete daily gains after starting treatment early in their disease course.
These are first-person, patient-reported accounts and have not been independently verified by this outlet. The patients do not claim a cure. Instead, they report that when anti-amyloid treatments were started early, the therapies appeared to slow decline enough to preserve meaningful daily abilities—walking, driving, working, volunteering and caring for family.
Patients share how anti-amyloid treatments helped
Dr. Brent Beasley, a retired internal medicine physician, says treatment helped him return to community roles he had lost, including serving as a deacon and teaching medical students. Lori Baetz, a retired engineering technician, says early treatment stopped the frightening episodes of getting lost and let her resume daily walks and routines.
Ralph Carmona reports he participated in a clinical trial and has since run marathons and continued public outreach and advisory work. Kathi Rigby credits treatment with improving memory and mental sharpness enough to remain active with her large family and community work. Michael B., now 85, says treatment helped restore his independence: he walks, exercises and continues to drive and engage with loved ones.
All five emphasize that lifestyle efforts—exercise, diet and social engagement—helped but were not enough on their own. Their shared message: early recognition of cognitive change created the window to pursue testing and treatment that made a practical difference in daily life.
Why anti-amyloid treatments work best with early diagnosis
Clinical trials and expert summaries indicate that some anti-amyloid therapies show their largest effects when given in the early stages of Alzheimer’s disease, before widespread irreversible neuronal loss. Randomized trials, including the phase 3 study published in the New England Journal of Medicine of lecanemab in early Alzheimer’s disease, reported a modest but statistically significant slowing of clinical decline compared with placebo. Such findings suggest earlier intervention—when amyloid is present but symptoms are less advanced—offers a greater chance to preserve function.
At the same time, clinicians and guideline authors caution that benefits vary by individual, that treatments carry risks (for example, treatment-related imaging abnormalities), and that outcomes observed in trials may not fully match real-world experience. Experts advise that biomarker testing and treatment decisions be made in the context of a comprehensive clinical evaluation.
New blood-based biomarker tests for Alzheimer’s-related proteins (for example, phosphorylated tau assays) can identify likely underlying Alzheimer pathology earlier and with less burden than some older methods such as PET scans or cerebrospinal fluid testing. Professional organizations and recent peer-reviewed studies note that plasma biomarkers are improving detection, but also emphasize confirmatory testing and specialist input when results will affect treatment decisions.
Access barriers: Medicare rules and insurance denials
The five patients and advocates interviewed say administrative and insurance hurdles limit access for people who might benefit. They point to Medicare administrative processes and private insurance denials as common obstacles to obtaining diagnostics and treatment.
Those denials can require appeals, additional testing, or specialist documentation, which may delay care at the moment when early treatment could be most helpful. Experiences with coverage and appeals vary widely by plan, Medicare contractor, state and individual clinical circumstances. Not all patients will face the same barriers.
Families should verify coverage directly with their insurer or Medicare plan. Useful steps include checking Medicare.gov and CMS resources, asking the plan for written reasons for any denial, requesting peer review or medical director review, documenting symptoms and tests carefully, and working with a memory clinic or specialist who can submit supporting records. Local and national advocates also recommend tracking timelines closely to avoid losing a treatment window.
What experts and advocates recommend now
Clinicians, researchers and patient advocates commonly recommend several concrete steps: expand access to validated blood tests, support primary care clinicians to screen and refer patients earlier, and prioritize equitable access so more families can evaluate treatment options sooner. Experts who summarize trial findings stress the need to balance modest average benefits against potential risks and costs, and to continue research into which patients benefit most.
Policy recommendations from advocates include reviewing payer requirements that create barriers, creating clear pathways for timely diagnostics and specialist referral, and investing in caregiver supports so patients can remain engaged at home as long as possible. Expanding diverse trial enrollment remains important to understand effectiveness across populations.
Practical steps for families and caregivers
Watch for early signs of cognitive change and raise concerns with a primary care clinician. Ask whether blood-based biomarker testing is appropriate and whether a referral to a memory clinic or dementia specialist is warranted. If testing or treatment is discussed, request clear documentation of clinical findings and test results to support any insurance submission or appeal.
For those seeking treatment, confirm coverage early, ask about prior authorization procedures, and be prepared to appeal with support from treating specialists. Consider clinical trials as an option; trials may provide access to therapies and more detailed monitoring. Caregivers should also pursue supports—respite services, local caregiver groups and planning resources—to help patients remain independent and engaged for as long as possible.
What comes next
New tools for detecting Alzheimer’s disease and therapies that target amyloid are changing the landscape, but broader access will depend on policy decisions, primary care practices, payer rules and further research. The shared accounts from these five patients highlight how earlier detection and timely treatment can translate into everyday independence for some people, while underscoring the need for careful clinical evaluation, verification of outcomes, and policy work to reduce access barriers.
Frequently asked questions
Who may benefit from anti-amyloid treatments?
Evidence and expert guidance suggest that people with early-stage Alzheimer’s disease or biomarker evidence of amyloid accumulation are most likely to benefit. Treatments are not cures; they may slow progression in some patients but not halt the disease. Eligibility depends on clinical evaluation, biomarker status, coexisting health issues and payer coverage.
How do blood tests help detect Alzheimer’s early?
Blood-based biomarker tests measure proteins associated with Alzheimer’s pathology and can identify people likely to have underlying disease earlier and with lower burden than some traditional methods. Positive blood tests typically prompt confirmatory testing and specialist referral before major treatment decisions.
Will Medicare cover these treatments and tests?
Coverage varies by plan, region and the specific therapy or diagnostic test. Some patients face prior authorizations or denials that require appeals. Families should check Medicare.gov, contact their plan or local Medicare administrative contractor for details, and work with clinicians to gather documentation if an appeal is needed.
Source (base reporting and patient accounts): Fox News — Alzheimer’s stole pieces of our lives. A new treatment is giving us a fighting chance
Additional context and peer-reviewed sources: Salloway S. et al., “Lecanemab in Early Alzheimer’s Disease,” New England Journal of Medicine (2023); Alzheimer’s Association guidance and information on biomarkers and care (alz.org); U.S. Centers for Medicare & Medicaid Services (cms.gov) for coverage and appeals information. These sources summarize trial results, biomarker developments and provide policy/coverage resources for families and clinicians.
